Germany
· Delayed Price · Currency is EUR BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of EUR 20.99 billion. The enterprise value is 5.87 billion.
| Market Cap | 20.99B |
| Enterprise Value | 5.87B |
Important Dates
The next estimated earnings date is Monday, May 5, 2025.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.95% |
| Shares Change (QoQ) | -1.75% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 92.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.63 |
| PB Ratio | 1.08 |
| P/TBV Ratio | 1.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 101.08 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.83 |
| EV / Sales | 2.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -74.51 |
Financial Position
The company has a current ratio of 7.45, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.45 |
| Quick Ratio | 7.26 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.23 |
| Interest Coverage | -102.02 |
Financial Efficiency
Return on equity (ROE) is -3.36% and return on invested capital (ROIC) is -4.00%.
| Return on Equity (ROE) | -3.36% |
| Return on Assets (ROA) | -3.53% |
| Return on Invested Capital (ROIC) | -4.00% |
| Return on Capital Employed (ROCE) | -6.43% |
| Revenue Per Employee | 406,246 |
| Profits Per Employee | -98,243 |
| Employee Count | 6,772 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 1.69 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.48% in the last 52 weeks. The beta is 1.08, so BioNTech SE's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | +10.48% |
| 50-Day Moving Average | 97.38 |
| 200-Day Moving Average | 98.15 |
| Relative Strength Index (RSI) | 47.11 |
| Average Volume (20 Days) | 1,743 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.11 |
Income Statement
In the last 12 months, BioNTech SE had revenue of EUR 2.75 billion and -665.30 million in losses. Loss per share was -2.77.
| Revenue | 2.75B |
| Gross Profit | 2.21B |
| Operating Income | -1.29B |
| Pretax Income | -677.70M |
| Net Income | -665.30M |
| EBITDA | -1.03B |
| EBIT | -1.29B |
| Loss Per Share | -2.77 |
Balance Sheet
The company has 16.78 billion in cash and 254.20 million in debt, giving a net cash position of 16.53 billion.
| Cash & Cash Equivalents | 16.78B |
| Total Debt | 254.20M |
| Net Cash | 16.53B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 19.41B |
| Book Value Per Share | 80.89 |
| Working Capital | 16.28B |
Cash Flow
In the last 12 months, operating cash flow was 207.70 million and capital expenditures -286.50 million, giving a free cash flow of -78.80 million.
| Operating Cash Flow | 207.70M |
| Capital Expenditures | -286.50M |
| Free Cash Flow | -78.80M |
| FCF Per Share | n/a |
Margins
Gross margin is 80.32%, with operating and profit margins of -46.73% and -24.18%.
| Gross Margin | 80.32% |
| Operating Margin | -46.73% |
| Pretax Margin | -24.63% |
| Profit Margin | -24.18% |
| EBITDA Margin | -37.55% |
| EBIT Margin | -46.73% |
| FCF Margin | n/a |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.95% |
| Shareholder Yield | 0.95% |
| Earnings Yield | -3.17% |
| FCF Yield | -0.38% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 6.17.
| Altman Z-Score | 6.17 |
| Piotroski F-Score | n/a |